Physician profile
Anna Declercq
NPI 1467165266
$346.86
in general payments reported to CMS, 2019-2025
11 companies · $347 in 2025
The $347 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $346.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $78.09 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.03 | 2025 | Caplyta |
| Pfizer INC. | $40.56 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.54 | 2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $27.93 | 2025 | Zoryve |
| Teva Pharmaceuticals USA, INC. | $25.21 | 2025 | Uzedy |
| Glaxosmithkline, LLC. | $22.49 | 2025 | Shingrix, Arexvy |
| Axsome Therapeutics, INC. | $21.91 | 2025 | Auvelity |
| Astrazeneca Pharmaceuticals Lp | $20.13 | 2025 | Airsupra |
| Collegium Pharmaceutical, INC. | $16.06 | 2025 | Belbuca |
| Lilly USA, LLC | $13.91 | 2025 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Declercq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.